VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2 (Q36419140)

14 August 2017

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2 (English)

1 reference

14 August 2017

1 reference

Athanasios Dimopoulos

13

object named as

M A Dimopoulos

1 reference

14 August 2017

N G Gavalas

1

1 reference

14 August 2017

M Tsiatas

2

1 reference

14 August 2017

O Tsitsilonis

3

1 reference

14 August 2017

E Politi

4

1 reference

14 August 2017

K Ioannou

5

1 reference

14 August 2017

A C Ziogas

6

1 reference

14 August 2017

A Rodolakis

7

1 reference

14 August 2017

G Vlahos

8

1 reference

14 August 2017

N Thomakos

9

1 reference

14 August 2017

D Haidopoulos

10

1 reference

14 August 2017

E Terpos

11

1 reference

14 August 2017

A Antsaklis

12

1 reference

14 August 2017

A Bamias

14

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

107

1 reference

14 August 2017

11

1 reference

14 August 2017

1869-1875

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2012.468

14 August 2017

0 references

cites work

VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

The role of microenvironment in tumor angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Angiogenic inhibitors: a new therapeutic strategy in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Immunosuppressive networks in the tumour environment and their therapeutic relevance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Vascular endothelial growth factor: basic science and clinical progress

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Tumorigenesis and the angiogenic switch

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Immune escape of tumors: apoptosis resistance and tumor counterattack.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Immunology. Tumor immune evasion.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

The role of VEGF pathways in human physiologic and pathologic angiogenesis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504940

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.468

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.468

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.468

Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation

21 January 2018

1 reference

12 December 2020

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

1 reference

12 December 2020

Hypoxia but not cigarette smoke modulates VEGF secretion from human T cells

1 reference

12 December 2020

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.468

1 reference

14 August 2017

1 reference

14 August 2017

1 reference